Skip to content
Screener

Axsome Therapeutics AXSM Contingent Consideration Liability (Non-Current)

Contingent Consideration Liability (Non-Current) at other companies

Alkermes logo
AlkermesALKS
——

Other financials

Income statement

See full
Revenue$191.2M+57.4%
Gross profit$176.5M+58.0%
Operating income-$63.4M-11.2%
Net income-$64.5M-8.6%
EPS (diluted)-$1.26-3.3%

Balance sheet

See full
Cash & equivalents$305.1M+1.4%
Total debt$219.9M+4.1%
Total equity$54.6M+2.6%
Total assets$713.6M+19.6%

Cash flow

See full
Operating cash flow-$20.7M+52.3%
CapEx$121.0K-64.2%
Free cash flow-$20.8M+52.4%

Valuation

See full
Market cap$10.81B+110%
Enterprise value$10.73B+112%
P/S15.3×+4.9×

Profitability

See full
Gross margin92.6%+1.1pp
Operating margin-24.4%-9.3pp
Net margin-26.6%-9.8pp
FCF margin-10.2%-3.9pp

Returns & leverage

See full
Return on equity-349.4%+109pp
Debt / equity4×+0.1×
Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent.

The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 5:04 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-204274
Line itemMarch 31,2026December 31,2025
Contingent consideration, current11,15010,012
Short-term borrowings70,00070,000
Total current liabilities439,211378,836
Contingent consideration, non-current73,73077,540
Loan payable, long-term117,850117,746
Operating lease liability, long-term22,38523,182
Finance lease liability, long-term5,8444,206
Total liabilities659,020601,510

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Axsome Therapeutics's contingent consideration liability (non-current)?
Axsome Therapeutics (AXSM) reported contingent consideration liability (non-current) of $73.73M in Q1 2026.
How has Axsome Therapeutics's contingent consideration liability (non-current) changed year-over-year?
Axsome Therapeutics's contingent consideration liability (non-current) decreased by 18.6% year-over-year, from $90.59M to $73.73M.
What is the long-term trend for Axsome Therapeutics's contingent consideration liability (non-current)?
Over 3 years (2022 to 2025), Axsome Therapeutics's contingent consideration liability (non-current) has grown at a 35.6% compound annual growth rate (CAGR), from $31.1M to $77.54M.
What does contingent consideration liability (non-current) mean?
This liability represents the estimated fair value of future payments owed as part of past business acquisitions, contingent upon specific milestones like regulatory approval or sales targets. It reflects long-term financial commitments tied to strategic growth initiatives.

Ask your AI about Axsome Therapeutics's contingent consideration liability (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude